Drug Master File (DMF) Submission

Maximize the protection of your proprietary drug information with Freyr's expert DMF submission services. From initial strategy to query resolution, we provide comprehensive support to streamline your DMF process and maintain Regulatory compliance.

Drug Master File (DMF) Submission - Overview

Proprietary and confidential information about the facilities and processes used in the manufacturing, processing, packaging, and excipients are included in a Drug Master File (DMF) and submitted to the United States Food and Drug Administration (US FDA) in support of the applications and other DMFs. A DMF submission is not mandatory. However, manufacturers submit the DMF to maintain the holder's proprietary information confidentiality.

During DMF filing, the information on the Active Pharmaceutical Ingredients (APIs)/intermediates, packaging materials, excipients, and facilities can be submitted to the US FDA under Type II, Type III, Type IV, and Type V DMFs respectively.

The Generic Drug User Fee Act (GDUFA II) is applicable for Type II DMF filing, which is intended for the submission of information for APIs. The Type II DMFs are assessed through a Letter of Access (LoA) to the applicants, so they can refer to the information in their applications (ANDA/NDA/IND/DMF) after the US FDA completes the Initial Completeness Assessment (ICA). Subsequently, a technical review of the DMF is performed by the US FDA in connection with the other applications. Any queries raised by the US FDA on the DMF content will delay the approval of the application filed by the applicant. 

Freyr has a Regulatory team with a deep understanding and experience in DMF filing that includes gap analysis, authoring and submission in the eCTD format, and managing & updating the DMFs per the latest guidelines by the FDA.

Drug Master File (DMF) Submission - Expertise

  • Regulatory submission strategy for different types of DMFs for drug substance (Type II), packaging materials (Type III) and Excipients (Type IV).
  • Identifying the Regulatory starting material.
  • Guidance on selection of route of synthesis for Drug Substance in line with US FDA expectations.
  • Support in designing the limits for impurities in starting materials, intermediates, and their carry-over to Active Pharmaceutical Ingredients (APIs).
  • Designing of specifications for starting materials, in-process, intermediates and drug substance.
  • Support in setting the strategy and limits for genotoxic impurities and elemental impurities in intermediates or Drug Substances.
  • Review support for the finalization of the development report with Quality by Design (QbD).
  • Guidance on designing the protocols for stability studies, process validation, hold time study, and forced degradation studies for Drug Master File submission.
  • Review of executed batch manufacturing records for adequacy.
  • Preparation and submission of Drug Master Files in line with GDUFA, Initial completeness assessment (ICA) requirements for Drug Substances.
  • Guidance for GDUFA fee compliance.
  • Publishing of DMFs in eCTD format as per current USFDA guidelines and requirements.
  • Regulatory strategy, preparation, and submission of amendments and annual reports for already registered Drug Master Files.
  • Regulatory strategy, preparation, and submission of the response to health authority queries.
Drug Master File (DMF) Submission

Celebrating Customers Success

 

Medicinal Products

Regulatory Affairs

India

Thank you for the timely support over the weekend, which allowed us to resubmit quickly after being notified. This continuously demonstrates Freyr's commitment towards our company’s milestones.

Director - Global Regulatory Affairs – Operations

India-based, Global Top Generic Pharma Company

 

Medicinal Products

Publishing

UK

I am sure you have heard by now that we have received our first-ever approval from the FDA for our Brands division. This is a major milestone for us as well as for my team here in Reg Ops. I would be remiss if I didn’t point out that we would not have been able to do this without the help of your dedicated team. From the original filing, then the following year of responses, all helped get us to final approval.

Thank you Freyr team for a job well done!

Sr. Director, Head of Regulatory Operations

Ireland-based, Global Specialty Pharmaceutical Company

 

Medicinal Products

Regulatory Affairs

USA

Please relate to the team the excellent job they have done on the IND reactivation. Specifically, the high-quality module 3, written by Freyr. It was very comprehensive, very few revisions were required, and we had no questions from Health Canada or FDA. No CMC questions: that was a first for me. So very responsive to my many requests, which I am sure can be frustrating but always helpful while producing excellent work.

Thank you for always being available and responding quickly and comprehensively to all my requests.

What a great team you have, Freyr.

Lynne McGrath

Regulatory Consultant

 

Medicinal Products

Regulatory Affairs

USA

Congratulations!!! ​

Thanks for your great support for a successful ANDA filing, especially to the publishing team. Heartfully appreciate their last hours of hard work.

Assistant Manager​

US-based, Leading, Complex Generic Pharmaceutical Products Company​

 

Medicinal Products

Regulatory Affairs

USA

Thank you all for the great support!​

CEO

US-based, Leading Innovative Pharmaceuticals Company​

 

Medicinal Products

Regulatory Affairs

USA

The ANDA receipt has been received! Thank you very much for your hard work, patience, and support for our work over the last couple of months. We are delighted that we were able to meet the timeline and hit an important corporate goal of our young company. ​

Thank you again, and we look forward to working with your team on the next project!

Senior Director of Business and Product Development​

US-based, Leading Innovator Pharmaceuticals Company​